Rasha Aboelhassan: Impressed by the results of the investigator-initiated TalaCom study
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:
“Cancer fighting is not only about treating patients.
It’s about finding new lines of treatment that can overcome resistance clones that grow every day.
I was impressed by reading the results of the investigator-initiated TalaCom study provide early evidence in favour of combining the PARP1/2 inhibitor talazoparib with the VEGFR inhibitor axitinib in patients with BRCA1/2 wildtype high-grade serous ovarian oe molecularly unselected metastatic castration-resistant prostate cancer.
This results will give chance for survival as well as Quality of life for patients in late stages of cancer. Thanks for all investigators.”
More posts featuring Rasha Aboelhassan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023